SM
IRLA

SG3 Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

SG3 Management’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-45
Closed -$825K – 1235
2021
Q3 		$825K Buy
+45
New +$716K 0.03% 496

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

SG3 Management's IRLA Position: Q4 2021 in Review

SG3 Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2021, closing a stake of 45 shares — an estimated $825K sold.

SG3 Management first reported a position in IRLA in Q3 2021 and held it in 1 quarter. The position peaked at $825K in Q3 2021. 98 funds tracked by Wall St. Rank hold IRLA as of Q4 2021.

  • SG3 Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 45 IRulya Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $825K.
  • SG3 Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • SG3 Management's IRulya Therapeutics Inc. Common Stock position peaked at $825K in Q3 2021.
  • 98 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.